<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T09:24:56Z</responseDate>
  <request identifier="oai:figshare.com:article/34035306" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34035306</identifier>
        <datestamp>2026-09-30T17:33:03Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_15</setSpec>
        <setSpec>category_16</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_122</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Participant flow diagram.&lt;/p&gt;</dc:title>
          <dc:creator>Julio Carlos Vélez de Lachica (25145304)</dc:creator>
          <dc:creator>Susana Serrano (683489)</dc:creator>
          <dc:creator>Eduard Vidovic (10071489)</dc:creator>
          <dc:creator>Antonio Farfan (25145307)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Physiology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Mental Health</dc:subject>
          <dc:subject>treatment &amp;# 8217</dc:subject>
          <dc:subject>generalized estimating equations</dc:subject>
          <dc:subject>also showed within</dc:subject>
          <dc:subject>81 – 20</dc:subject>
          <dc:subject>52 – 21</dc:subject>
          <dc:subject>showed consistent improvement</dc:subject>
          <dc:subject>patellofemoral joint loading</dc:subject>
          <dc:subject>clinically meaningful improvement</dc:subject>
          <dc:subject>subgroup analyses assessed</dc:subject>
          <dc:subject>findings support intra</dc:subject>
          <dc:subject>related knee pain</dc:subject>
          <dc:subject>describe longitudinal changes</dc:subject>
          <dc:subject>bmi subgroup (&lt;</dc:subject>
          <dc:subject>koos scores increased</dc:subject>
          <dc:subject>2 &lt;/ sup</dc:subject>
          <dc:subject>predefined ikdc threshold</dc:subject>
          <dc:subject>sorbitol injection outcomes</dc:subject>
          <dc:subject>xlink "&gt; athletes</dc:subject>
          <dc:subject>patellofemoral pain</dc:subject>
          <dc:subject>longitudinal changes</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>n &lt;/</dc:subject>
          <dc:subject>koos threshold</dc:subject>
          <dc:subject>koos scores</dc:subject>
          <dc:subject>improvement rate</dc:subject>
          <dc:subject>group improvement</dc:subject>
          <dc:subject>clinical outcomes</dc:subject>
          <dc:subject>knee function</dc:subject>
          <dc:subject>estimated changes</dc:subject>
          <dc:subject>sorbitol injection</dc:subject>
          <dc:subject>tolerated option</dc:subject>
          <dc:subject>small elevated</dc:subject>
          <dc:subject>sensitivity analysis</dc:subject>
          <dc:subject>potential influence</dc:subject>
          <dc:subject>may contribute</dc:subject>
          <dc:subject>functional limitation</dc:subject>
          <dc:subject>frequent cause</dc:subject>
          <dc:subject>exploratory regression</dc:subject>
          <dc:subject>exploratory comparisons</dc:subject>
          <dc:subject>controlled trials</dc:subject>
          <dc:subject>ci 17</dc:subject>
          <dc:subject>ci 16</dc:subject>
          <dc:subject>body weight</dc:subject>
          <dc:subject>athletic populations</dc:subject>
          <dc:subject>6 months</dc:subject>
          <dc:description>&lt;p&gt;Sixty-four consecutive athletes with a clinical diagnosis of patellofemoral pain were enrolled and received a single intra-articular hyaluronic acid–sorbitol injection. Four participants were excluded during follow-up, 60 participants completed all four assessment points and were included in the complete-case analysis.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-30T17:32:58Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0346269.g001</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Participant_flow_diagram_p_/34035306</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
